Similar articles

• HIV-1 and HAART: a time to cure, a time to kill.

  Saag MS, Kilby JM. Saag MS, et al. Nat Med. 1999 Jun;5(6):609-11. doi: 10.1038/9452. Nat Med. 1999. PMID: 10371490 No abstract available.
• IL-2 taken to HAART.

  Gilden D. Gilden D. GMHC Treat Issues. 1999 Feb;13(2):4-6. GMHC Treat Issues. 1999. PMID: 11366116
• Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.

  Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci AS. Chun TW, et al. Nat Med. 1999 Jun;5(6):651-5. doi: 10.1038/9498. Nat Med. 1999. PMID: 10371503 Clinical Trial.
• Immunologic reconstitution by interleukin-2: facts and open questions.

  Vallanti G, Bovolenta C, Brambilla A, Tambussi G, Lazzarin A, Vicenzi E, Poli G. Vallanti G, et al. J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):41-4. J Biol Regul Homeost Agents. 2000. PMID: 10763892 Review.
• Effect of antiretroviral therapy on plasma HIV RNA.

  Saag MS. Saag MS. J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):105-6. J Biol Regul Homeost Agents. 1995. PMID: 8782017 Review. No abstract available.